Adropin Is Expressed in Pancreatic Islet Cells and Reduces Glucagon Release in Diabetes Mellitus

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 28

PMID 39337311

Authors

Ifrah I Ali

Crystal DSouza

Saeed Tariq

Ernest A Adeghate

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus affects 537 million adults around the world. Adropin is expressed in different cell types. Our aim was to investigate the cellular localization in the endocrine pancreas and its effect on modulating pancreatic endocrine hormone release in streptozotocin (STZ)-induced diabetic rats. Adropin expression in the pancreas was investigated in normal and diabetic rats using immunohistochemistry and immunoelectron microscopy. Serum levels of insulin, glucagon pancreatic polypeptide (PP), and somatostatin were measured using a Luminex χMAP (Magpix) analyzer. Pancreatic endocrine hormone levels in INS-1 832/3 rat insulinoma cells, as well as pancreatic tissue fragments of normal and diabetic rats treated with different concentrations of adropin (10, 10, and 10 M), were measured using ELISA. Adropin was colocalized with cells producing either insulin, glucagon, or PP. Adropin treatment reduced the number of glucagon-secreting alpha cells and suppressed glucagon release from the pancreas. The serum levels of GLP-1 and amylin were significantly increased after treatment with adropin. Our study indicates a potential role of adropin in modulating glucagon secretion in animal models of diabetes mellitus.

References

Thapa D, Xie B, Manning J, Zhang M, Stoner M, Huckestein B . Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep. 2019; 7(8):e14043. PMC: 6474842. DOI: 10.14814/phy2.14043. View

Bottcher G, Ahren B, Lundquist I, Sundler F . Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas. 1989; 4(3):282-8. View

Atkinson M, Eisenbarth G . Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001; 358(9277):221-9. DOI: 10.1016/S0140-6736(01)05415-0. View

Ludvik B, Thomaseth K, Nolan J, Clodi M, Prager R, Pacini G . Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest. 2003; 33(4):316-22. DOI: 10.1046/j.1365-2362.2003.01142.x. View

le Roux C, Batterham R, Aylwin S, Patterson M, Borg C, Wynne K . Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2005; 147(1):3-8. DOI: 10.1210/en.2005-0972. View

Adeghate E, Ponery A, Pallot D, Singh J . Distribution of vasoactive intestinal polypeptide, neuropeptide-Y and substance P and their effects on insulin secretion from the in vitro pancreas of normal and diabetic rats. Peptides. 2001; 22(1):99-107. DOI: 10.1016/s0196-9781(00)00361-2. View

Jasaszwili M, Billert M, Strowski M, Nowak K, Skrzypski M . Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research. Molecules. 2020; 25(3). PMC: 7036858. DOI: 10.3390/molecules25030549. View

Ramracheya R, Chapman C, Chibalina M, Dou H, Miranda C, Gonzalez A . GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca channels. Physiol Rep. 2018; 6(17):e13852. PMC: 6125244. DOI: 10.14814/phy2.13852. View

Elayat A, El-Naggar M, Tahir M . An immunocytochemical and morphometric study of the rat pancreatic islets. J Anat. 1995; 186 ( Pt 3):629-37. PMC: 1167020. View

10.

Liu Z, Kim W, Chen Z, Shin Y, Carlson O, Fiori J . Insulin and glucagon regulate pancreatic α-cell proliferation. PLoS One. 2011; 6(1):e16096. PMC: 3026810. DOI: 10.1371/journal.pone.0016096. View

11.

Altamimi T, Gao S, Karwi Q, Fukushima A, Rawat S, Wagg C . Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 2019; 98:37-48. DOI: 10.1016/j.metabol.2019.06.005. View

12.

Atkinson M, Eisenbarth G, Michels A . Type 1 diabetes. Lancet. 2013; 383(9911):69-82. PMC: 4380133. DOI: 10.1016/S0140-6736(13)60591-7. View

13.

Zhao Y, Zhou Y, Xiao M, Huang Y, Qi M, Kong Z . Impaired glucose tolerance is associated with enhanced postprandial pancreatic polypeptide secretion. J Diabetes. 2022; 14(5):334-344. PMC: 9366580. DOI: 10.1111/1753-0407.13268. View

14.

Kiriyama Y, Nochi H . Role and Cytotoxicity of Amylin and Protection of Pancreatic Islet β-Cells from Amylin Cytotoxicity. Cells. 2018; 7(8). PMC: 6115925. DOI: 10.3390/cells7080095. View

15.

Chen L, Lu J, Hu J, Gong X . Unveiling the multifaceted role of adropin in various diseases (Review). Int J Mol Med. 2024; 54(4). PMC: 11335353. DOI: 10.3892/ijmm.2024.5414. View

16.

Brereton M, Vergari E, Zhang Q, Clark A . Alpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination?. J Histochem Cytochem. 2015; 63(8):575-91. PMC: 4530398. DOI: 10.1369/0022155415583535. View

17.

Lotfy M, Singh J, Rashed H, Tariq S, Zilahi E, Adeghate E . Mechanism of the beneficial and protective effects of exenatide in diabetic rats. J Endocrinol. 2013; 220(3):291-304. DOI: 10.1530/JOE-13-0426. View

18.

Holst J, Gasbjerg L, Rosenkilde M . The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. 2021; 162(7). PMC: 8168943. DOI: 10.1210/endocr/bqab065. View

19.

Gao S, McMillan R, Zhu Q, Lopaschuk G, Hulver M, Butler A . Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015; 4(4):310-24. PMC: 4354928. DOI: 10.1016/j.molmet.2015.01.005. View

20.

Martinez M, Manzano A, Olivar L, Nava M, Salazar J, DMarco L . The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror. Int J Mol Sci. 2021; 22(17). PMC: 8431704. DOI: 10.3390/ijms22179504. View